Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

SANGRAM S. PARELKAR, PhD

Dewpoint Therapeutics, Massachusetts, United States

Sangram has over 22 years of experience in drug discovery and delivery. As a Principal Scientist at Dewpoint Therapeutics, he leads high content screening, hit to lead, and supports lead optimization campaigns for novel condensate modifiers (c-mods) for a broad range of diseases.
Prior to joining Dewpoint, at Valo Health he developed unique cellular and biochemical assays and performed multiple 0.5 million compound high throughput screens using automation and state of the art technologies. Before Valo, as a Senior Scientist at the UMass Chan Medical School he worked in chemical biology and along with Professor Paul Thompson co-built and expanded the capabilities of the Small Molecule Screening Facility (SMSF). At the SMSF he performed biochemical, biophysical and cellular high throughput screens across multiple diseases areas ranging from neurology and oncolology to viral diseases including Zika and COVID-19.
Sangram received a Ph.D. in Molecular and Cellular Biology at UMass Amherst where he worked under the guidance of Professor Lawrence Schwartz on the role of aggresomes in Parkinson's Disease. He also did a post-doctoral under Professor Todd Emrick at the Polymer Science and Engineering where he worked in multidisciplinary teams to develop novel biomaterials and non-viral drug delivery approaches.

Disclosure information not submitted.

Presentation(s):